Welcome to NewJerseyLifeScience.com
NewJerseyLifeScience.com is part of a specialized network of state based biotechnology, medical device,
and life science sites that includes more than 3,500 biotechnology, medical device, pharmaceutical companies,
non-profit research institutions, universities and supporting service sector companies across the U.S.
This network addresses the growing informational and service needs of companies, patients, educators and others in
their respective states while providing clients the opportunity to cost effectively
advertise their job openings, events, facility availability and other services at the state level,
regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting
services.
More...
|
|
Learn About New Jersey's BioHistory
Why is there a biotechnology industry in New Jersey? Will the industry continue
to grow in New Jersey? What do other states have? Each state has a unique story
that explains why a given industry has developed in a specific region and not in others.
Through New Jersey BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industries in the state of New Jersey.
More NJ BioHistory...
|
Local News...
Free News Release Posting & Archiving Service
- Insecticide Movento(R) approved in United States and Canada The new insecticidal active ingredient spirotetramat from Bayer CropScience has been granted regulatory approval in the strategically important markets in the United States and Canada. Spirotetramat will be marketed worldwide under the brand name Movento(R).
Bayer July 03, 2008
- Adolor provides update on Entereg(R) (alvimopan) OBD Program Adolor Corporation issued an update on the Entereg(R) (alvimopan) Program for chronic opioid bowel dysfunction (OBD), under development in collaboration with GlaxoSmithKline. The FDA has concluded that clinical investigations relating to alvimopan in OBD may now proceed.
Adolor Corporation July 03, 2008
- OSI Pharmaceuticals announces conversion period for Convertible Notes OSI Pharmaceuticals announced that its 2% Convertible Senior Notes due 2025 are now convertible at the option of the holders and will remain convertible through September 30, 2008, the last trading day of the current fiscal quarter, as provided for in the Indenture governing the notes.
OSI Pharmaceuticals, Inc. July 03, 2008
- Wyeth and Progenics receive approval from European Commission for RELISTOR Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals announced that the companies have received marketing approval for RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection from the European Commission.
Progenics Pharmaceuticals, Inc. July 03, 2008
- Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen Bayer HealthCare is expanding its commitment to hemophilia with the acquisition of Maxygen's hemophilia program assets, including a next-generation recombinant Factor VIIa protein known as MAXY-VII. The lead therapeutic candidate is expected to enter Phase 1 clinical testing in 3Q 2008.
Bayer July 02, 2008
More... | Submit News Release | National News
|